A ranar 10 ga Fabrairu, 2025, CARsgen Therapeutics ta sanar da cewa mutum na farko da aka yi wa magani da maganin allogeneic BCMA CAR-T wanda aka haɓaka akan dandamalin THANK-u Plus™, ya sami cikakken martani (sCR) da ƙarancin rashin lafiyar sauran cututtuka (MRD) a kimantawar Rana ta 28. An haɓaka dandamalin THANK-u Plus™ a cikin gida, fasahar allogeneic CAR-T ce mai ƙirƙira don shawo kan ƙalubalen samun damar shiga a cikin maganin CAR-T.
Majinyacin, wanda aka gano yana da cutar myeloma mai sake dawowa/rashin daidaituwa, nau'in IgA-λ (R-ISS Stage II), ya riga ya yi amfani da hanyoyi uku na maganin hadewa tare da dashen ƙwayoyin halitta na autologous hematopoietic. Bayan ci gaban cutar bayan magani na baya-bayan nan, an shigar da majinyacin cikin gwajin asibiti. Bayan jiko ƙwayoyin CAR T a mafi ƙarancin allurai bisa ga ka'idar asibiti, majinyacin ya sami ciwon sakin cytokine na Grade 1 (CRS), wanda aka yi masa magani mai kyau da magungunan antipyretics da tocilizumab, kuma majinyacin bai nuna ciwon neurotoxicity da ke da alaƙa da ƙwayoyin cuta (ICANS) ko wasu abubuwan da suka faru na rashin lafiyar garkuwar jiki da ke da alaƙa da CAR-T ba, wanda ke nuna kyakkyawan yanayin aminci.
An ƙirƙiri wannan maganin CAR-T don maganin sake dawowa/rage yawan myeloma (R/R MM) da kuma sake dawowa/rage yawan cutar sankarar jini ta plasma (R/R PCL). Ana sa ran ƙarin sabunta bayanai a rabin na biyu na wannan shekarar.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Email：myimmnet@163.com
Nassoshi
2.https://www.prnasia.com/
Lokacin Saƙo: Fabrairu-11-2025